Álvaro Gutiérrez-Viedma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Álvaro Gutiérrez-Viedma has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
B. Parejo-Carbonell
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, España; Unidad de Epilepsia, Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España
4 shared publicationsI. García-Morales
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Unidad de Epilepsia, Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
4 shared publicationsI. Serrano-García
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Unidad de Metodología de Investigación y Epidemiología Clínica, Servicio de Medicina Preventiva, Hospital Clínico San Carlos, Madrid, Spain
4 shared publicationsIrene García-Morales
4 shared publicationsM. Romeral-Jiménez
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Unidad de Epilepsia, Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
4 shared publications- Estevo Santamarina
Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Spain
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Epilepsia Open
Implementation of the seizure code in a tertiary hospital: Effects on emergency care times and clinical outcomes in severe seizures
Objective: To assess the impact of implementing the Seizure Code (SC), a structured multidisciplinary emergency protocol for severe seizures, on care times and clinical outcomes at a tertiary hospital. Methods: Single‐center, retrospective observational study including episodes of severe seizures in patients aged 18 years or older managed between January 2023 and December 2024, comparing pre‐SC and post‐SC periods. The primary outcome was time from seizure onset to administration of the first anti‐seizure medication (ASM). Secondary outcomes included other care intervals, process indicators, and clinical outcomes. Care intervals were analyzed with accelerated failure time models (percentage change in median time), length of stay in a competing‐risks framework, and binary outcomes with Firth‐penalized logistic regression (odds ratios, OR), all adjusted for prespecified covariates and clustered by patient. Results: Of 1959 episodes identified, 378 (175 pre‐SC, 203 post‐SC) met SC activation criteria. Time to the first ASM, the primary outcome, did not differ significantly (27% shorter, 95% CI ‐15% to 53% for benzodiazepines; 27%, −6% to 50% for others). Time to urgent video‐EEG (VEEG) was 48% shorter (29%–61%) and the neurological assessment‐VEEG interval 63% shorter (31%–80%). Pre‐notification by Emergency Medical Services increased (22.9% vs. 37.8%; p = 0.003). Hospital stay (7.48 vs. 5.08 days; subdistribution hazard ratio for discharge alive 1.36, 1.02–1.89) and intensive care unit stay (3.20 vs. 1.48 days) were shorter. Thirty‐day seizure recurrence was lower (8.0% vs. 3.0%; adjusted OR 0.33, 0.12–0.84). Mortality and functional status at discharge did not differ. Significance: The primary outcome, time to first anti‐seizure medication, was not significantly shorter after implementation of the structured emergency protocol. The observed benefits were concentrated in secondary process and resource‐utilization indicators: implementation of the Seizure Code was associated with faster access to urgent VEEG, shorter hospital and intensive care unit stays, and lower 30‐day seizure recurrence, without a significant effect on mortality. These findings support protocolized emergency pathways in severe seizures. Plain Language Summary: Severe seizures are emergencies in which fast, coordinated care matters. We compared how patients were treated at one hospital before and after a new protocol, the Seizure Code, was introduced. Afterwards, patients had urgent video‐EEG (a recording of brain activity) sooner and spent fewer days in hospital and in the intensive care unit, and fewer had another seizure within 30 days. However, the time to the first anti‐seizure medication did not change significantly, and deaths and disability at discharge were unchanged.
- 5 November 2026
- Published by Wiley in Epilepsia Open
Open AccessImplementation of the seizure code in a tertiary hospital: Effects on emergency care times and clinical outcomes in severe seizures
Objective: To assess the impact of implementing the Seizure Code (SC), a structured multidisciplinary emergency protocol for severe seizures, on care times and clinical outcomes at a tertiary hospital. Methods: Single‐center, retrospective observational study including episodes of severe seizures in patients aged 18 years or older managed between January 2023 and December 2024, comparing pre‐SC and post‐SC periods. The primary outcome was time from seizure onset to administration of the first anti‐seizure medication (ASM). Secondary outcomes included other care intervals, process indicators, and clinical outcomes. Care intervals were analyzed with accelerated failure time models (percentage change in median time), length of stay in a competing‐risks framework, and binary outcomes with Firth‐penalized logistic regression (odds ratios, OR), all adjusted for prespecified covariates and clustered by patient. Results: Of 1959 episodes identified, 378 (175 pre‐SC, 203 post‐SC) met SC activation criteria. Time to the first ASM, the primary outcome, did not differ significantly (27% shorter, 95% CI ‐15% to 53% for benzodiazepines; 27%, −6% to 50% for others). Time to urgent video‐EEG (VEEG) was 48% shorter (29%–61%) and the neurological assessment‐VEEG interval 63% shorter (31%–80%). Pre‐notification by Emergency Medical Services increased (22.9% vs. 37.8%; p = 0.003). Hospital stay (7.48 vs. 5.08 days; subdistribution hazard ratio for discharge alive 1.36, 1.02–1.89) and intensive care unit stay (3.20 vs. 1.48 days) were shorter. Thirty‐day seizure recurrence was lower (8.0% vs. 3.0%; adjusted OR 0.33, 0.12–0.84). Mortality and functional status at discharge did not differ. Significance: The primary outcome, time to first anti‐seizure medication, was not significantly shorter after implementation of the structured emergency protocol. The observed benefits were concentrated in secondary process and resource‐utilization indicators: implementation of the Seizure Code was associated with faster access to urgent VEEG, shorter hospital and intensive care unit stays, and lower 30‐day seizure recurrence, without a significant effect on mortality. These findings support protocolized emergency pathways in severe seizures. Plain Language Summary: Severe seizures are emergencies in which fast, coordinated care matters. We compared how patients were treated at one hospital before and after a new protocol, the Seizure Code, was introduced. Afterwards, patients had urgent video‐EEG (a recording of brain activity) sooner and spent fewer days in hospital and in the intensive care unit, and fewer had another seizure within 30 days. However, the time to the first anti‐seizure medication did not change significantly, and deaths and disability at discharge were unchanged.
- 8 March 2023
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 94 (9) , 776-777
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study
From the onset of SARS-CoV-2 pandemic, world population has been affected by high levels of stress, uncertainty and misleading information, with a potential impact on mental health. Different studies have ascertained an increase of FND consultations (threefold in an emergency department).2 On the development of SARS-CoV-2 vaccines, several cases of FND following vaccination were published, as well as an official warning from the Functional Neurological Society.3 Post-COVID-19 symptoms (known as Long-COVID-19) have also become a frequent reason for neurology consultation.4 Somatic symptom disorder may be common in these patients, and socioeconomic implications are vast.5
- 8 March 2023
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 94 (9) , 776-777
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study
From the onset of SARS-CoV-2 pandemic, world population has been affected by high levels of stress, uncertainty and misleading information, with a potential impact on mental health. Different studies have ascertained an increase of FND consultations (threefold in an emergency department).2 On the development of SARS-CoV-2 vaccines, several cases of FND following vaccination were published, as well as an official warning from the Functional Neurological Society.3 Post-COVID-19 symptoms (known as Long-COVID-19) have also become a frequent reason for neurology consultation.4 Somatic symptom disorder may be common in these patients, and socioeconomic implications are vast.5
- Open Access
- 1 January 2023
- Published by Elsevier in Neurología (English Edition)
- Vol. 38 (1) , 29-34
Seizures in the Emergency Department: clinical and diagnostic data from a series of 153 patients
- 1 January 2023
- Published by Elsevier in Neurología (English Edition)
- Vol. 38 (1) , 29-34
Open AccessSeizures in the Emergency Department: clinical and diagnostic data from a series of 153 patients
- Open Access
- 1 January 2023
- Published by Elsevier in Neurología
- Vol. 38 (1) , 30-35
Crisis epilépticas en urgencias: aspectos clínicos y diagnósticos de una serie de 153 pacientes
- 1 January 2023
- Published by Elsevier in Neurología
- Vol. 38 (1) , 30-35
Open AccessCrisis epilépticas en urgencias: aspectos clínicos y diagnósticos de una serie de 153 pacientes
- Open Access
- 1 May 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 37 (4) , 263-270
The importance of timing in epilepsia partialis continua
- 1 May 2022
- Published by Elsevier in Neurología (English Edition)
- Vol. 37 (4) , 263-270
Open AccessThe importance of timing in epilepsia partialis continua
- Open Access
- 1 May 2022
- Published by Elsevier in Neurología
- Vol. 37 (4) , 263-270
La relevancia del tiempo en la epilepsia parcial continua
- 1 May 2022
- Published by Elsevier in Neurología
- Vol. 37 (4) , 263-270
Open AccessLa relevancia del tiempo en la epilepsia parcial continua
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114, 107570
Epidaily, a scale for comprehensive functional assessment of patients with epilepsy
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114, 107570
Epidaily, a scale for comprehensive functional assessment of patients with epilepsy
- 19 October 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 143 (3) , 281-289
Therapy delay in status epilepticus extends its duration and worsens its prognosis
Background Timing in status epilepticus (SE) attention is probably the most relevant modifiable prognostic factor, and may influence SE duration and prognosis. We aimed to describe the precise relationship between management timing, duration, and prognosis of SE. Methods Observational longitudinal prospective study on a cohort of all patients diagnosed with SE admitted to our tertiary hospital from September 2017 to August 2019, with a 3‐month follow up. Univariate and multivariable analyses were performed to identify clinical and timing variables associated with SE duration and prognosis. Results Eighty‐three SE affecting 76 patients were included. Median age was 73 years, 61.4% were women, median baseline modified Rankin Scale (mRS) was 2, and 55.4% had prior epilepsy. In the out‐of‐hospital group (n=50), median time to Emergencies was 1.3 hours, and to hospital admission 2.8 hours. In the global series, median time to neurologist was 4.3 hours, and median time to therapy initiation was 4.5 hours. These four times positively correlated with SE duration (all Spearman´s rho coefficient>0.5, all p<0.001). SE median duration was 24 hours, and was extended 1.2 hours for each hour of treatment delay. A longer SE duration was associated with increased mortality and morbidity, both at hospital discharge and at 3‐month follow up (both p<0.05). After 3 months, mortality was 30.1%, while recovery to baseline mRS occurred in 39.5%, with an overall median mRS of 4. Conclusions There were pervasive delays in all phases of SE attention, which conditioned a longer SE duration, and this led to increased long‐term morbimortality.
- 19 October 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 143 (3) , 281-289
Therapy delay in status epilepticus extends its duration and worsens its prognosis
Background Timing in status epilepticus (SE) attention is probably the most relevant modifiable prognostic factor, and may influence SE duration and prognosis. We aimed to describe the precise relationship between management timing, duration, and prognosis of SE. Methods Observational longitudinal prospective study on a cohort of all patients diagnosed with SE admitted to our tertiary hospital from September 2017 to August 2019, with a 3‐month follow up. Univariate and multivariable analyses were performed to identify clinical and timing variables associated with SE duration and prognosis. Results Eighty‐three SE affecting 76 patients were included. Median age was 73 years, 61.4% were women, median baseline modified Rankin Scale (mRS) was 2, and 55.4% had prior epilepsy. In the out‐of‐hospital group (n=50), median time to Emergencies was 1.3 hours, and to hospital admission 2.8 hours. In the global series, median time to neurologist was 4.3 hours, and median time to therapy initiation was 4.5 hours. These four times positively correlated with SE duration (all Spearman´s rho coefficient>0.5, all p<0.001). SE median duration was 24 hours, and was extended 1.2 hours for each hour of treatment delay. A longer SE duration was associated with increased mortality and morbidity, both at hospital discharge and at 3‐month follow up (both p<0.05). After 3 months, mortality was 30.1%, while recovery to baseline mRS occurred in 39.5%, with an overall median mRS of 4. Conclusions There were pervasive delays in all phases of SE attention, which conditioned a longer SE duration, and this led to increased long‐term morbimortality.
- 1 October 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 99, 106467
Patients' knowledge on epilepsy and SUDEP improves after a semi-structured health interview
- 1 October 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 99, 106467
Patients' knowledge on epilepsy and SUDEP improves after a semi-structured health interview
Use of intravenous brivaracetam in status epilepticus: A multicenter registry
Objective: The pharmacokinetics of brivaracetam (BRV), added to its effectiveness observed in animal models of status epilepticus (SE), makes this drug attractive for use in emergency situations. Our objective was to evaluate the use of intravenous BRV in a multicenter study.Methods: A retrospective multicenter registry of SE cases treated with BRV was created. These patients were evaluated between January and December 2018 at seven hospitals in Spain. Demographic variables, SE characteristics, concomitant drugs, loading doses, and response to treatment were collected.Results: Forty‐three patients were registered. The mean age was 56 ± 23.1 years, 51.2% were male, 29 had previous epilepsy, 24 (55.8%) had prominent motor symptoms, and 19 had nonconvulsive symptoms. Regarding the etiology, 19 (44.2%) were considered acute symptomatic, 16 (17.2%) remote symptomatic, four (9.3%) progressive symptomatic, and four (9.3%) cryptogenic. Regarding concomitant antiepileptic drugs (AEDs), 17 had previously received levetiracetam (LEV). In 14 patients, BRV was used early (first or second AED). The median loading dose was 100 mg (range = 50‐400), and the weight‐adjusted dose was 1.8 mg/kg (range = 0.4‐7.3). BRV was effective in 54% (n = 23), and a response was observed in P = 0.09), but there were no differences regarding SE type and the concomitant use of LEV. In those with the fastest responses, we observed that both the total administered dose (300 mg vs 100 mg, P = 0.008) and the weight‐adjusted dose (3.85 mg vs 1.43 mg, P = 0.006) were significantly higher. The receiver operating characteristic curve showed that the best cutoff point for a faster response was 1.82 mg/kg.Significance: BRV is useful for the treatment of SE, even when patients are already being treated with LEV. The response rate seems higher when it is administered earlier and at higher doses (>1.82 mg/kg).
Use of intravenous brivaracetam in status epilepticus: A multicenter registry
Objective: The pharmacokinetics of brivaracetam (BRV), added to its effectiveness observed in animal models of status epilepticus (SE), makes this drug attractive for use in emergency situations. Our objective was to evaluate the use of intravenous BRV in a multicenter study.Methods: A retrospective multicenter registry of SE cases treated with BRV was created. These patients were evaluated between January and December 2018 at seven hospitals in Spain. Demographic variables, SE characteristics, concomitant drugs, loading doses, and response to treatment were collected.Results: Forty‐three patients were registered. The mean age was 56 ± 23.1 years, 51.2% were male, 29 had previous epilepsy, 24 (55.8%) had prominent motor symptoms, and 19 had nonconvulsive symptoms. Regarding the etiology, 19 (44.2%) were considered acute symptomatic, 16 (17.2%) remote symptomatic, four (9.3%) progressive symptomatic, and four (9.3%) cryptogenic. Regarding concomitant antiepileptic drugs (AEDs), 17 had previously received levetiracetam (LEV). In 14 patients, BRV was used early (first or second AED). The median loading dose was 100 mg (range = 50‐400), and the weight‐adjusted dose was 1.8 mg/kg (range = 0.4‐7.3). BRV was effective in 54% (n = 23), and a response was observed in P = 0.09), but there were no differences regarding SE type and the concomitant use of LEV. In those with the fastest responses, we observed that both the total administered dose (300 mg vs 100 mg, P = 0.008) and the weight‐adjusted dose (3.85 mg vs 1.43 mg, P = 0.006) were significantly higher. The receiver operating characteristic curve showed that the best cutoff point for a faster response was 1.82 mg/kg.Significance: BRV is useful for the treatment of SE, even when patients are already being treated with LEV. The response rate seems higher when it is administered earlier and at higher doses (>1.82 mg/kg).